New subgroup analyses from the TULIP Phase III clinical trial ...
The Pharma Letter - 01 Nov 2021New subgroup analyses from the TULIP Phase III clinical trial program showed Saphnelo (anifrolumab), a first-in-class type I interferon antagonist, ...